Perrigo Wants Answers From Former Owner Of Its Branded Consumer Business
This article was originally published in The Pink Sheet
Perrigo reported a $804m impairment for its European branded OTC drug and nutritional products business for the July-September period and will file an arbitration claim against its former owners. Company also highlights Rx-to-OTC switch opportunities.
You may also be interested in...
OTC private label/store brand giant announces Irish authorities allow it to pay $308.7m to settle a $1.9bn assessment for back taxes ordered in 2018 linked to Rx ingredient royalty rights it gained in its 2103 merger with Elan.
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.
Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.